Anhui Anke Biotechnology (300009.SZ) and its subsidiary will exclusively distribute Recombinant human follicle-stimulating hormone-CTP fusion protein injection.

Anhui Anke Biotechnology (300009.SZ) announced that the recombinant human follicle stimulating hormone-CTP fusion protein injection developed by its wholly-owned subsidiary Suzhou Shengji Pharmaceutical Co., Ltd. ("Shengji Pharmaceutical"), known as "SJ02", is about to be launched. The company and its wholly-owned subsidiary Anhui Anke Pharmaceutical Co., Ltd. ("Anke Pharmaceutical") reached a cooperation agreement with Shengji Pharmaceutical on July 9, 2025, and signed an "Exclusive Product Agency Agreement". The company and Anke Pharmaceutical will exclusively represent the SJ02 product for sales and marketing promotion in mainland China, Hong Kong, Macau, and Taiwan. The announcement stated that the recombinant human follicle stimulating hormone-CTP fusion protein injection is a long-acting recombinant human follicle stimulating hormone (FSH-CTP) combined with a gonadotropin releasing hormone (GnRH) antagonist for controlled ovarian stimulation (COS). Shengji Pharmaceutical submitted the SJ02 drug registration application to the National Medical Products Administration in December 2023, and it is expected to become the first domestically approved long-acting FSH-CTP product. SJ02 can reduce multiple injections to a single dose, greatly reducing the treatment burden on users, and has higher convenience and compliance.